| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18445 R78342 |
Lee (Controls exposed to SSRI), 2025 | 5-minute Apgar score<7 | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: TCA only |
2.40 [0.69;8.32] C excluded (control group) |
5/613 5/1,465 | 10 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18410 R77743 |
Lee (Controls unexposed, general pop), 2025 | 5-minute Apgar score<7 | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: TCA only | 1.61 [0.65;3.99] | 5/613 1,721/463,440 | 1,726 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18222 R76452 |
Martin - Amitriptyline, 2024 | Low Apgar score at 5 min (<7) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.94 [0.70;1.26] | 51/2,899 30,996/2,078,011 | 31,047 | 2,899 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11668 R42787 |
Källen, 2013 | Apgar score at 5min <7 | 2nd and/or 3rd trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: no or not specified | 2.07 [1.23;3.27] | 18/394 -/- | - | 394 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10935 R40673 |
Simon (Controls exposed to SSRIs), 2002 | Apgar score at 5 minutes ≤7 | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: TCA only |
0.41 [0.19;0.91] C excluded (control group) |
10/209 20/185 | 30 | 209 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10936 R40689 |
Simon (Controls unexposed, NOS), 2002 | Apgar score at 5 minutes ≤7 | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: TCA only | 1.29 [0.47;2.22] | 10/209 8/209 | 18 | 209 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.36 [0.87;2.14] | 32,791 | 4,115 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop; 2: Controls unexposed, NOS;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10935, 18445